Description
Vemlidy (Tenofovir Alafenamide) 25mg Online
Vemlidy (Tenofovir Alafenamide) is used to treat chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. Vemlidy (TAF) is a nucleotide reverse transcriptase inhibitor (NRTI) and a novel ester prodrug of the antiretroviral Vemlidy. Following oral administration, TAF is converted in vivo to Vemlidy, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5′-monophosphate.
Vemlidy mimics normal DNA building blocks but is lacking a 3′-OH molecule required for phosphodiester bond linkage. By competing with regular nucleotides for incorporation into proviral DNA and prevention of the formation of the 5′ to 3′ phosphodiester linkage required for DNA elongation, Vemlidy causes early chain termination and prevents proviral DNA transcription. Although Vemlidy (available as Vemlidy disoproxil fumarate) has a good safety profile and efficacy and is currently a cornerstone of HIV antiviral treatment, its use has been associated with nephrotoxicity and reduced bone mineral density. In comparison, TAF has been shown to have improved antiviral efficacy, enhanced delivery of TFV into peripheral blood mononuclear cells (PBMCs) and lymphatic tissues, a higher barrier to resistance, and an improved safety profile. Improved renal safety is likely attributable to lower circulating plasma concentrations of Vemlidy and therefore less exposure and damage to bone and the kidneys, where Vemlidy is metabolized. Because HIV antiretroviral therapy is usually life-long, reduced toxicity and improved efficacy result in better patient outcomes and improved adherence in the long term. Vemlidy is currently available in two fixed-dose combination products: Odefsey (emtricitabine, rilpivirine, and Vemlidy), and Descovy (emtricitabine and Vemlidy). Both products are indicated for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
